{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:25:25Z","timestamp":1707524725403},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,23]]},"DOI":"10.7759\/cureus.31819","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T13:15:07Z","timestamp":1669209307000},"source":"Crossref","is-referenced-by-count":2,"title":["Grade III Severe QT Prolongation in an Indian Male on All-Oral Longer Regimen for Multidrug-Resistant Pulmonary Tuberculosis: World\u2019s First Case"],"prefix":"10.7759","author":[{"given":"Sankalp","family":"Yadav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229691","article-title":"Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017","volume":"15","author":"Edwards BD","year":"2020","unstructured":"Edwards BD, Edwards J, Cooper R, Kunimoto D, Somayaji R, Fisher D. Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017. PLoS One. 2020, 15:e0229691. 10.1371\/journal.pone.0229691","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27163","article-title":"Primary isoniazid mono-resistant pulmonary tuberculosis in a COVID-19-positive male: world's first case of its kind in the present pandemic","volume":"14","author":"Yadav S","year":"2022","unstructured":"Yadav S. Primary isoniazid mono-resistant pulmonary tuberculosis in a COVID-19-positive male: world's first case of its kind in the present pandemic. Cureus. 2022, 14:e27163. 10.7759\/cureus.27163","journal-title":"Cureus"},{"key":"ref3","unstructured":"World Health Organization. global tuberculosis report 2022. (2022). Accessed: November 10, 2022: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2022."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-007490","article-title":"Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study","volume":"7","author":"Perrin C","year":"2022","unstructured":"Perrin C, Athersuch K, Elder G, Martin M, Alsalhani A. Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study. BMJ Glob Health. 2022, 7:e007490. 10.1136\/bmjgh-2021-007490","journal-title":"BMJ Glob Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"1016","author":"Tiberi S","year":"2018","unstructured":"Tiberi S, du Plessis N, Walzl G, et al.. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018, 1016:1473-3099. 10.1016\/S1473-3099(18)30110-5","journal-title":"Lancet Infect Dis"},{"key":"ref6","unstructured":"Drug resistant TB India. (2021). Accessed. November 1, 2022: https:\/\/tbfacts.org\/drug-resistant-tb-india\/."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30764","article-title":"Adverse drug reaction monitoring in multidrug-resistant tuberculosis patients receiving bedaquiline and delamanid-based regimen","volume":"14","author":"Paikray E","year":"2022","unstructured":"Paikray E, Das P, Pattnaik M, Mishra V. Adverse drug reaction monitoring in multidrug-resistant tuberculosis patients receiving bedaquiline and delamanid-based regimen. Cureus. 2022, 14:30764. 10.7759\/cureus.30764","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2016\/15395.7096","article-title":"Primary extrapulmonary multidrug-resistant tuberculosis of the sternum without HIV infection","volume":"10","author":"Yadav S","year":"2016","unstructured":"Yadav S, Rawal G. Primary extrapulmonary multidrug-resistant tuberculosis of the sternum without HIV infection. J Clin Diagn Res. 2016, 10:RD01-3. 10.7860\/JCDR\/2016\/15395.7096","journal-title":"J Clin Diagn Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2016\/19052.8286","article-title":"Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis","volume":"10","author":"Yadav S","year":"2016","unstructured":"Yadav S, Rawal G, Baxi M. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. J Clin Diagn Res. 2016, 10:FM01-2. 10.7860\/JCDR\/2016\/19052.8286","journal-title":"J Clin Diagn Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2174\/157488610789869247","article-title":"Mechanisms of drug induced QT interval prolongation","volume":"5","author":"Ponte ML","year":"2010","unstructured":"Ponte ML, Keller GA, Di Girolamo G. Mechanisms of drug induced QT interval prolongation. Curr Drug Saf. 2010, 5:44-53. 10.2174\/157488610789869247","journal-title":"Curr Drug Saf"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5152\/akd.2015.5875","article-title":"QT interval variations and mortality risk: is there any relationship?","volume":"15","author":"Rezu\u015f C","year":"2015","unstructured":"Rezu\u015f C, Moga VD, Ouatu A, Floria M. QT interval variations and mortality risk: is there any relationship?. Anatol J Cardiol. 2015, 15:255-8. 10.5152\/akd.2015.5875","journal-title":"Anatol J Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.37506\/ijfmt.v15i4.17119","article-title":"A woman with tuberculosis multidrug resistance and QTc prolongation repetitive interval: a case report","volume":"15","author":"Kusmiati T","year":"2021","unstructured":"Kusmiati T, Mertaniasih NM, Putranto JNE, Suprapti B, Soedarsono, Bahmid AR. A woman with tuberculosis multidrug resistance and QTc prolongation repetitive interval: a case report. Indian J Forensic Med Toxicol. 2021, 15:4. 10.37506\/ijfmt.v15i4.17119","journal-title":"Indian J Forensic Med Toxicol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.21010\/ajidv15i2S.5","article-title":"Incidence of high grade QTcF prolongation and its management among patients undergoing treatment for drug resistant tuberculosis (DR-TB): case series","volume":"15","author":"Asfaw MT","year":"2021","unstructured":"Asfaw MT, Holtzman DL, Kwan GF, Oyewusi LT, Mitnick CD, Seung KJ. Incidence of high grade QTcF prolongation and its management among patients undergoing treatment for drug resistant tuberculosis (DR-TB): case series. Afr J Infect Dis. 2021, 15:38-41. 10.21010\/ajidv15i2S.5","journal-title":"Afr J Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-6621.2020.07.009","article-title":"Effect of bedaquiline-containing regimen on QT interval in patients with multidrug-resistant tuberculosis","volume":"42","author":"Li X","year":"2020","unstructured":"Li X, Jing-tao G, Li-ping M, et al..  Effect of bedaquiline-containing regimen on QT interval in patients with multidrug-resistant tuberculosis. Chin J Antituberc. 2020, 42:687-94. 10.3969\/j.issn.1000-6621.2020.07.009","journal-title":"Chin J Antituberc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0174","article-title":"Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease","volume":"21","author":"Yoon HY","year":"2017","unstructured":"Yoon HY, Jo KW, Nam GB, Shim TS. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. Int J Tuberc Lung Dis. 2017, 21:996-1001. 10.5588\/ijtld.17.0174","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley KE","year":"2021","unstructured":"Dooley KE, Rosenkranz SL, Conradie F, et al.. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021, 21:975-83. 10.1016\/S1473-3099(20)30770-2","journal-title":"Lancet Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/125921-grade-iii-severe-qt-prolongation-in-an-indian-male-on-all-oral-longer-regimen-for-multidrug-resistant-pulmonary-tuberculosis-worlds-first-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:16Z","timestamp":1707507796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/125921-grade-iii-severe-qt-prolongation-in-an-indian-male-on-all-oral-longer-regimen-for-multidrug-resistant-pulmonary-tuberculosis-worlds-first-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.31819","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,23]]}}}